{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:41:31Z","timestamp":1778834491202,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["19013"],"award-info":[{"award-number":["19013"]}],"id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["19013"],"award-info":[{"award-number":["19013"]}],"id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["19013"],"award-info":[{"award-number":["19013"]}],"id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2739\/A2289"],"award-info":[{"award-number":["C2739\/A2289"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2739\/A2289"],"award-info":[{"award-number":["C2739\/A2289"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2739\/A2289"],"award-info":[{"award-number":["C2739\/A2289"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19 disease. Therapeutic antibodies are being developed that interact with the viral spike proteins to limit viral infection of epithelium. We have applied a method to dramatically improve the performance of anti-SARS-CoV-2 antibodies by enhancing avidity through multimerization using simple engineering to yield tetrameric antibodies. We have re-engineered six anti-SARS-CoV-2 antibodies using the human p53 tetramerization domain, including three clinical trials antibodies casirivimab, imdevimab and etesevimab. The method yields tetrameric antibodies, termed quads, that retain efficient binding to the SARS-CoV-2 spike protein, show up to two orders of magnitude enhancement in neutralization of pseudovirus infection and retain potent interaction with virus variant of concern spike proteins. The tetramerization method is simple, general and its application is a powerful methodological development for SARS-CoV-2 antibodies that are currently in pre-clinical and clinical investigation.<\/jats:p>","DOI":"10.1038\/s41598-021-89887-w","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T10:04:35Z","timestamp":1621332275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins"],"prefix":"10.1038","volume":"11","author":[{"given":"Adam","family":"Leach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"Mattiuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jemima","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"McAndrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Van Montfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Rabbitts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"89887_CR1","doi-asserted-by":"publisher","first-page":"1752529","DOI":"10.1080\/19420862.2020.1752529","volume":"12","author":"A Miller","year":"2020","unstructured":"Miller, A., Carr, S., Rabbitts, T. & Ali, H. Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats. MAbs 12, 1752529 (2020).","journal-title":"MAbs"},{"key":"89887_CR2","doi-asserted-by":"crossref","unstructured":"Dhama, K., Patel, S.K., Sharun, K., Pathak, M., Tiwari, R., Yatoo, M.I., Malik, Y.S., Sah, R., Rabaan, A.A., Panwar, P.K., Singh, K.P., Michalak, I., Chaicumpa, W., Martinez-Pulgarin, D.F., Bonilla-Aldana, D.K. & Rodriguez-Morales, A.J. SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Med. Infect. Dis. 37, 101830 (2020).","DOI":"10.1016\/j.tmaid.2020.101830"},{"key":"89887_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875\u2013879 (2005).","journal-title":"Nat. Med."},{"key":"89887_CR4","doi-asserted-by":"crossref","unstructured":"Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., Muller, M.A., Drosten, C., & Pohlmann, S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 e8 (2020).","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"89887_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"89887_CR6","doi-asserted-by":"crossref","unstructured":"Cao, Y., et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell 182, 73\u201384 e16 (2020).","DOI":"10.1016\/j.cell.2020.05.025"},{"key":"89887_CR7","doi-asserted-by":"crossref","unstructured":"Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. (2020).","DOI":"10.1056\/NEJMoa2029849"},{"key":"89887_CR8","doi-asserted-by":"crossref","unstructured":"ter Meulen, J., van den Brink, E.N., Poon, L.L., Marissen, W.E., Leung, C.S., Cox, F., Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., van Deventer, E., Preiser, W., Doerr, H.W., Chow, V.T., de Kruif, J., Peiris, J.S. & Goudsmit, J. Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med. 3, e237 (2006).","DOI":"10.1371\/journal.pmed.0030237"},{"key":"89887_CR9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","journal-title":"Science"},{"key":"89887_CR10","doi-asserted-by":"crossref","unstructured":"Seydoux, E. et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity 53, 98\u2013105 e5 (2020).","DOI":"10.1016\/j.immuni.2020.06.001"},{"key":"89887_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"89887_CR12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278 (2020).","journal-title":"Science"},{"key":"89887_CR13","doi-asserted-by":"publisher","first-page":"22370","DOI":"10.1038\/s41598-020-79036-0","volume":"10","author":"TJ Esparza","year":"2020","unstructured":"Esparza, T. J., Martin, N. P., Anderson, G. P., Goldman, E. R. & Brody, D. L. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci. Rep. 10, 22370 (2020).","journal-title":"Sci. Rep."},{"key":"89887_CR14","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"89887_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","volume":"27","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27, 846\u2013854 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"89887_CR16","doi-asserted-by":"crossref","unstructured":"Wrapp, D., De Vlieger, D., Corbett, K.S., Torres, G.M., Wang, N., Van Breedam, W., Roose, K., van Schie, L., V.-C.C.-R. Team, Hoffmann, M., Pohlmann, S., Graham, B.S., Callewaert, N., Schepens, B., Saelens, X. & McLellan, J.S. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell 181, 1004\u20131015 e15 (2020).","DOI":"10.1016\/j.cell.2020.04.031"},{"key":"89887_CR17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1126\/science.abe4747","volume":"370","author":"Y Xiang","year":"2020","unstructured":"Xiang, Y. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479\u20131484 (2020).","journal-title":"Science"},{"key":"89887_CR18","unstructured":"Bracken, C.J., Lim, S.A., Solomon, P., Rettko, N.J., Nguyen, D.P., Zha, B.S., Schaefer, K., Byrnes, J.R., Zhou, J., Lui, I., Liu, J., Pance, K., Q.S.B. Consortium, Zhou, X.X., Leung, K.K. & Wells, J.A. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat. Chem. Biol. 17, 113\u2013121 (2021)."},{"key":"89887_CR19","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1038\/s41467-020-19204-y","volume":"11","author":"TF Custodio","year":"2020","unstructured":"Custodio, T. F. et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat. Commun. 11, 5588 (2020).","journal-title":"Nat. Commun."},{"key":"89887_CR20","doi-asserted-by":"crossref","unstructured":"Li, W., et al. High potency of a bivalent human VH domain in SARS-CoV-2 animal models. Cell 183, 429\u2013441 e16 (2020).","DOI":"10.1016\/j.cell.2020.09.007"},{"key":"89887_CR21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.abe3255","volume":"370","author":"M Schoof","year":"2020","unstructured":"Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473\u20131479 (2020).","journal-title":"Science"},{"key":"89887_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41587-020-0732-8","volume":"38","author":"L DeFrancesco","year":"2020","unstructured":"DeFrancesco, L. COVID-19 antibodies on trial. Nat. Biotechnol. 38, 1242\u20131252 (2020).","journal-title":"Nat. Biotechnol."},{"key":"89887_CR23","doi-asserted-by":"crossref","unstructured":"Greaney, A.J., et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. bioRxiv (2020).","DOI":"10.1101\/2020.09.10.292078"},{"key":"89887_CR24","doi-asserted-by":"crossref","unstructured":"Hodcroft, E.B., Zuber, M., Nadeau, S., Crawford, K.H.D., Bloom, J.D., Veesler, D., Vaughan, T.G., Comas, I., Candelas, F.G., Stadler, T. & Neher, R.A. Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. medRxiv (2020).","DOI":"10.1101\/2020.10.25.20219063"},{"key":"89887_CR25","unstructured":"Kemp, S.A. et al. Neutralising antibodies in spike mediated SARS-CoV-2 adaptation. medRxiv (2020)."},{"key":"89887_CR26","doi-asserted-by":"crossref","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827 e19 (2020).","DOI":"10.1016\/j.cell.2020.06.043"},{"key":"89887_CR27","unstructured":"Popa, A. et al. Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Sci. Transl. Med. 12 (2020)."},{"key":"89887_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1073\/pnas.1015520107","volume":"108","author":"R Melero","year":"2011","unstructured":"Melero, R. et al. Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA. Proc. Natl. Acad. Sci. U S A 108, 557\u2013562 (2011).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"89887_CR29","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","volume":"11","author":"C Lei","year":"2020","unstructured":"Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 11, 2070 (2020).","journal-title":"Nat. Commun."},{"key":"89887_CR30","doi-asserted-by":"crossref","unstructured":"Miller, A., Leach, A., Thomas, J., McAndrew, C., Bentley, E., Mattiuzzo, G., John, L., Mirazimi, A., Harris, G., Gamage, N., Carr, S., Ali, H., van Montfort, R.L. & Rabbitts, T.H. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. (2021) (submitted for publication).","DOI":"10.21203\/rs.3.rs-151560\/v1"},{"key":"89887_CR31","unstructured":"Weinreich, D.M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. (2020)."},{"key":"89887_CR32","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1096\/fj.08-111484","volume":"22","author":"CY Fan","year":"2008","unstructured":"Fan, C. Y. et al. Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold. FASEB J. 22, 3795\u20133804 (2008).","journal-title":"FASEB J."},{"key":"89887_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1042\/BJ20070149","volume":"406","author":"M Liu","year":"2007","unstructured":"Liu, M. et al. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb. Biochem. J. 406, 237\u2013246 (2007).","journal-title":"Biochem. J."},{"key":"89887_CR34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/icb.2010.21","volume":"88","author":"X Zhu","year":"2010","unstructured":"Zhu, X. et al. COMBODY: One-domain antibody multimer with improved avidity. Immunol. Cell Biol. 88, 667\u2013675 (2010).","journal-title":"Immunol. Cell Biol."},{"key":"89887_CR35","doi-asserted-by":"crossref","unstructured":"Liu, H., Wu, N.C., Yuan, M., Bangaru, S., Torres, J.L., Caniels, T.G., van Schooten, J., Zhu, X., Lee, C.D., Brouwer, P.J.M., van Gils, M.J., Sanders, R.W., Ward, A.B. & Wilson, I.A. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. Immunity 53, 1272\u20131280 e5 (2020).","DOI":"10.1016\/j.immuni.2020.10.023"},{"key":"89887_CR36","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature (2021).","DOI":"10.3410\/f.739524179.793585051"},{"key":"89887_CR37","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1093\/nar\/30.2.e9","volume":"30","author":"Y Durocher","year":"2002","unstructured":"Durocher, Y., Perret, S. & Kamen, A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9 (2002).","journal-title":"Nucleic Acids Res."},{"key":"89887_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-4939-2272-7_12","volume":"1266","author":"M Fairhead","year":"2015","unstructured":"Fairhead, M. & Howarth, M. Site-specific biotinylation of purified proteins using BirA. Methods Mol. Biol. 1266, 171\u2013184 (2015).","journal-title":"Methods Mol. Biol."},{"key":"89887_CR39","doi-asserted-by":"crossref","unstructured":"Carnell, G., Grehan, K., Ferrera, F., Molesti, E. & Temperton, N. An optimized method for the production using PEI, tritration and neutralization of SARS-CoV spike luciferase pseudotypes. Bio-protocol 7, e2514 (2017).","DOI":"10.21769\/BioProtoc.2514"},{"key":"89887_CR40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"R Zufferey","year":"1997","unstructured":"Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871\u2013875 (1997).","journal-title":"Nat. Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89887-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89887-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89887-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:33:08Z","timestamp":1670056388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89887-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89887"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89887-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"20 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Terence Rabbitts is a stake holder in Quadrucept Ltd. None of the other authors have any conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10475"}}